Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Institut Jean Paoli & Irene Calmettes is active in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This prosecution activity is handled by 1 distinct examiner and 1 distinct art unit, indicating a singular focus for the institute's current patent office engagements. The narrow distribution suggests that the institute's current legal efforts are directed toward a single specific application. Practitioners should note that the involvement of 1 distinct art unit simplifies the administrative tracking of the application.
The busiest examiner for this portfolio is CHASE, CAROL ANN, who manages 1 busiest examiner pending office action. This count matches the total of 1 pending office action for the entire portfolio, showing that this examiner is responsible for all active legal proceedings. Because there is only 1 distinct examiner, the prosecution environment is highly centralized for the applicant. Practitioners should note that the 1 busiest examiner pending office action represents the total active workload, requiring focused attention on this single individual's review process to ensure the institute's patent goals are met.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHASE, CAROL ANN | 1 | 42.6% | +84.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998584 | NEW METHOD TO TREAT CUTANEOUS T-CELL LYMPHOMAS AND TFH DERIVED LYMPHOMAS | CHASE, CAROL ANN | 13d |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17998584 | NEW METHOD TO TREAT CUTANEOUS T-CELL LYMPHOMAS AND TFH DERIVED LYMPHOMAS | CHASE, CAROL ANN | 1646 | §103 | Non-Final OA | 13d | Pending | Nov 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial